Opin vísindi

Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children

Skoða venjulega færslu

dc.contributor.author Schaffer, Andrea L.
dc.contributor.author Bruno, Claudia
dc.contributor.author Buckley, Nicholas A.
dc.contributor.author Cairns, Rose
dc.contributor.author Litchfield, Melisa
dc.contributor.author Paget, Simon
dc.contributor.author Zoega, Helga
dc.contributor.author Nassar, Natasha
dc.contributor.author Pearson, Sallie Anne
dc.date.accessioned 2022-12-23T01:03:54Z
dc.date.available 2022-12-23T01:03:54Z
dc.date.issued 2022-02-16
dc.identifier.citation Schaffer , A L , Bruno , C , Buckley , N A , Cairns , R , Litchfield , M , Paget , S , Zoega , H , Nassar , N & Pearson , S A 2022 , ' Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children ' , Paediatric and Perinatal Epidemiology , vol. 36 , no. 5 , pp. 726-737 . https://doi.org/10.1111/ppe.12870
dc.identifier.issn 0269-5022
dc.identifier.other 68599500
dc.identifier.other a5ff0715-9d97-45f9-94e2-0ae31985bae6
dc.identifier.other 85124723330
dc.identifier.other 35172017
dc.identifier.other unpaywall: 10.1111/ppe.12870
dc.identifier.uri https://hdl.handle.net/20.500.11815/3785
dc.description Funding Information: This research is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900). AS is supported by an NHMRC Early Career Fellowship (ID: 1158763). RC is supported by an NHMRC Emerging Leadership Investigator Grant (ID: 1196516). HZ is supported by a UNSW Scientia Fellowship. NN is supported by the Financial Markets Foundation for Children. CB is supported by an Australian Government Research Training Program Scholarship We thank the Australian Government Services Australia, for providing the data. Open access publishing facilitated by University of New South Wales, as part of the Wiley - University of New South Wales agreement via the Council of Australian University Librarians. Funding Information: This research is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (ID: 1196900). AS is supported by an NHMRC Early Career Fellowship (ID: 1158763). RC is supported by an NHMRC Emerging Leadership Investigator Grant (ID: 1196516). HZ is supported by a UNSW Scientia Fellowship. NN is supported by the Financial Markets Foundation for Children. CB is supported by an Australian Government Research Training Program Scholarship Publisher Copyright: © 2022 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd.
dc.description.abstract BACKGROUND: Medicine prescribing for children is impacted by a lack of paediatric-specific dosing, efficacy and safety data for many medicines. OBJECTIVES: To estimate the prevalence of medicine use among children and the rate of 'off-label' prescribing according to age at dispensing. METHODS: We used population-wide primarily outpatient dispensing claims data for 15% of Australian children (0-17 years), 2013-2017 (n = 840,190). We estimated prescribed medicine use and 'off-label' medicine use according to the child's age (<1 year, 1-5 years, 6-11 years, 12-17 years) defined as medicines without age-appropriate dose recommendations in regulator-approved product information. Within off-label medicines, we also identified medicines with and without age-specific dose recommendations in a national prescribing guide, the Australian Medicines Handbook Children's Dosing Companion (AMH CDC). RESULTS: The overall dispensing rate was 2.0 dispensings per child per year. The medicines with the highest average yearly prevalence were systemic antibiotics (435.3 per 1000 children), greatest in children 1-5 years (546.9 per 1000). Other common medicine classes were systemic corticosteroids (92.7 per 1000), respiratory medicines (91.2 per 1000), acid-suppressing medicines in children <1 year (47.2 per 1000), antidepressants in children 12-17 years (40.3 per 1000) and psychostimulants in children 6-11 years (27.0 per 1000). We identified 12.2% of dispensings as off-label based on age, but 66.3% of these had age-specific dosing recommendations in the AMH CDC. Among children <1 year, off-label dispensings were commonly acid-suppressing medicines (35.5%) and topical hydrocortisone (33.1%); in children 6-11 years, off-label prescribing of clonidine (16.0%) and risperidone (13.1%) was common. Off-label dispensings were more likely to be prescribed by a specialist (21.7%) than on-label dispensings (7.5%). CONCLUSIONS: Prescribed medicine use is common in children, with off-label dispensings for medicines without paediatric-specific dosing guidelines concentrated in classes such as acid-suppressing medicines and psychotropics. Our findings highlight a need for better evidence to support best-practice prescribing.
dc.format.extent 12
dc.format.extent 859246
dc.format.extent 726-737
dc.language.iso en
dc.relation.ispartofseries Paediatric and Perinatal Epidemiology; 36(5)
dc.rights info:eu-repo/semantics/openAccess
dc.subject attention deficit disorder with hyperactivity
dc.subject Australia
dc.subject gastroesophageal reflux
dc.subject paediatrics
dc.subject pharmacoepidemiology
dc.subject Off-Label Use
dc.subject Prevalence
dc.subject Humans
dc.subject Australia/epidemiology
dc.subject Infant
dc.subject Practice Patterns, Physicians'
dc.subject Anti-Bacterial Agents
dc.subject Child
dc.subject Pediatrics, Perinatology and Child Health
dc.subject Epidemiology
dc.title Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1111/ppe.12870
dc.relation.url http://www.scopus.com/inward/record.url?scp=85124723330&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu